Tokyo - Delayed Quote JPY

Sumitomo Pharma Co., Ltd. (4506.T)

1,884.50 -60.50 (-3.11%)

At close: October 30 at 3:30:00 PM GMT+9

Chart Range Bar

Loading chart for 4506.T

Previous Close 1,945.00
Open 1,931.00
Bid 1,884.50 x --
Ask 1,889.00 x --
Day's Range 1,883.00 - 1,963.00
52 Week Range 1,188.00 - 3,288.00
Volume 3,578,800
Avg. Volume 3,945,101
Market Cap (intraday) 845.374B
Beta (5Y Monthly) 0.47
PE Ratio (TTM) 7.71
EPS (TTM) 244.56
Earnings Date (est.) Jan 29, 2027
Forward Dividend & Yield 30.00 (1.59%)
Ex-Dividend Date Mar 30, 2027
1y Target Est 2,242.86

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

www.sumitomo-pharma.com

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4506.T

18.70%

Nikkei 225 (^N225)

25.73%

1-Year Return

4506.T

10.20%

Nikkei 225 (^N225)

23.31%

3-Year Return

4506.T

340.51%

Nikkei 225 (^N225)

106.18%

5-Year Return

4506.T

21.29%

Nikkei 225 (^N225)

119.05%

Earnings Per Share (GAAP)

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY27

Revenue 137B

Earnings 21.24B

Profit Margin 15.50%

FY26

FY27

50B

100B

0.0%

5.0%

10.0%

15.0%

Analyst Price Targets

1,500.00 Low

2,242.86 Average

1,884.50 Current

2,800.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

23.73%
Return on Assets (ttm)

3.92%
Return on Equity (ttm)

38.53%
Revenue (ttm)

474.79B
Net Income Avi to Common (ttm)

112.66B
Diluted EPS (ttm)

244.56

Balance Sheet and Cash Flow

Total Cash (mrq)

76.64B
Total Debt/Equity (mrq)

39.32%
Levered Free Cash Flow (ttm)

80.34B

4523.T

4507.T

4503.T

4519.T

4578.T

U.S. markets closed

Sumitomo Pharma Co., Ltd. (4506.T)

2.56%

15.86%

9.60%

-18.70%

10.20%

17.27%

236.52%

Sumitomo Pharma Co., Ltd. Overview Drug Manufacturers - Specialty & Generic / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share (GAAP)

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch